Packaging error leads to birth control pill recall in US

May 30, 2018

Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy.

The company says four placebo pills were placed out of order in the Taytulla packs. Allergan says the first four days of therapy had four non-hormonal placebo capsules instead of active capsules.

The recall involves lot 5620706, which expires in May 2019. Consumers who have those should arrange to return them to their physicians.

Consumers with questions about the recall are being asked to contact Allergan at 800-678-1605, Monday through Friday.

Explore further: Women's wellness: Birth control pill benefits, risks and choices

Related Stories

Women's wellness: Birth control pill benefits, risks and choices

April 23, 2018
The birth control pill is surrounded by misinformation. Get the facts on common concerns and questions about taking the pill. If you take the birth control pill (oral contraceptive), you're probably happy with its convenience ...

Pfizer recalls 1 million packets of US birth control pills

February 1, 2012
US pharmaceutical giant Pfizer on Wednesday recalled one million packets of birth control pills over a packaging error that could put women at risk of unintended pregnancy.

US recalls India-made birth control pills

February 27, 2012
A batch of birth control pills manufactured in India for US distribution has been recalled due to a packaging error that could make the pills ineffective, US health authorities said on Monday.

Allergan tells shareholders to reject Valeant deal

June 23, 2014
Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and that shareholders should reject it.

Valeant launches hostile $53B bid for Allergan

June 18, 2014
Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

Teva expect to close $40.5B Allergan generic deal next week

July 27, 2016
Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators ...

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.